EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. – ...
October 22 2015 - 9:44PM
Rosen Law Firm, a global investor rights law firm, announces that a
class action lawsuit has been filed on behalf of purchasers of
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) securities from March
8, 2013 through August 20, 2015, all dates inclusive (the “Class
Period”). The lawsuit seeks to recover damages for Northwest
Biotherapeutics, Inc. investors under the federal securities
laws.
To join the Northwest Biotherapeutics, Inc. class
action, go to the firm’s website at
http://www.rosenlegal.com/cases-299.html or call Phillip Kim, Esq.
or Kevin Chan, Esq. toll-free at 866-767-3653 or email
pkim@rosenlegal.com or kchan@rosenlegal.com for information on the
class action. The lawsuit is pending in U.S. District Court
for the District of Maryland.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE
ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY
COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS
MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR
CHOICE.
According to the lawsuit, Defendants made false
and/or misleading statements and/or failed to disclose that: (1)
Northwest Biotherapeutics’ claims concerning positive results from
its DCVax-Direct Trial were based on preliminary and unverified
trial results; (2) the DCVax-Direct Trial results on which
Northwest Biotherapeutics reported had not been assessed or
examined by the hospitals conducting the trials; (3) Northwest
Biotherapeutics’ statements about DCVax-Direct were derived from
patient case report forms that the hospitals were obliged to send
to Northwest Biotherapeutics only because it sponsored the study;
(4) Northwest Biotherapeutics was the subject of an aggressive
stock promotion campaign which included promoters using fictitious
identities and false credentials; (5) German regulators required
additional information from Northwest Biotherapeutics so that the
DCVax-L Trial could continue uninterrupted; and (6) consequently,
Northwest Biotherapeutics’ financial statements were materially
false and misleading at all relevant times. When the true details
entered the market, the lawsuit claims that investors suffered
damages.
A class action lawsuit has already been filed. If
you wish to serve as lead plaintiff, you must move the Court no
later than October 26, 2015. A lead plaintiff is a representative
party acting on behalf of other class members in directing the
litigation. If you wish to join the litigation, go to the firm’s
website at http://www.rosenlegal.com/cases-299.html or to discuss
your rights or interests regarding this class action, please
contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm
toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or
kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the
globe, concentrating its practice in securities class actions and
shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2024 to May 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From May 2023 to May 2024